An interventional study of Quercetin (dietary supplement) and Coenzyme Q10 in Healthy Aging, Inflammaging and Metabolic Health, sponsored by Applied Science & Performance Institute. Recruiting at 1 site in United States. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Applied Science & Performance Institute · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to learn if Quercefit® or Ubiqsome™ can improve markers of healthy aging, blood sugar control, and heart health in older adults. It will also learn about the safety of these supplements.
The main questions it aims to answer are:
Researchers will compare Quercefit® (500 mg/day), Ubiqsome™ (300 mg/day), and a placebo (a look-alike capsule with no active ingredient).
Participants will:
Go to a preferred clinic at the start and end of the study for a fasting blood draw
Complete at-home tests:
This study will be a randomized, double-blind, placebo-controlled clinical study conducted over a 12-week intervention investigating the effects of Quercefit® (500 mg daily, 250 mg twice daily), Ubiqsome™ (300 mg daily, 150 mg twice daily), or a placebo (twice daily). Participants will be recruited nationally in a decentralized format and will complete testing procedures remotely, with blood draws conducted through partner labs and electronic survey assessments. Key biomarkers of inflammaging, phenotypic aging, biological age, glucose regulation, insulin sensitivity, insulin resistance, lipid profile, and cardiovascular health will be examined through repeated assessments as described below.
This study will enroll 60 sedentary men and women, selected based on the inclusion and exclusion criteria defined in the protocol. Only individuals who meet all inclusion criteria and none of the exclusion criteria will be considered eligible. Recruitment will occur through an online participant database, through which applicants will be sent initial subject material. To begin enrollment, participants will complete screening to verify they are clinically overweight to obese (BMI ≥ 25.00 kg/m²), are sedentary men and women aged 50 to 75 years old, and are free of chronic cardiovascular, neurological, hepatic, renal, or metabolic disease, as determined by a health history questionnaire. As part of the screening process, participants will also be required to score 5 or higher on the CDC's prediabetes risk test (https://www.cdc.gov/prediabetes/takethetest). Finally, participants must not currently be using glucose-lowering agents or insulin.
Upon passing all inclusion and exclusion criteria, participants will confirm their address and general availability. Before any study-related procedures are completed, participants will be asked to review and sign an informed consent form. Afterward, participants will be assigned a designated requisition form for blood collection at their preferred Labcorp location. During week one of testing, after a minimum 10-hour overnight fast from food, participants will arrive at the preferred Labcorp location confirmed during enrollment and complete a venipuncture-based blood draw for the collection of fasting biomarkers. This panel will include markers used to calculate composite inflammaging burden (CIMKDM), phenotypic age, metabolic health (glucose, insulin, HbA1c, HOMA-IR, QUICKI), lipid and cardiovascular risk factors, organ function (liver, kidney), inflammatory mediators (CRP, cortisol), and complete blood count with differential. Lab results will be emailed to research staff approximately 3 to 5 business days post-collection.
On a separate day that same week, participants will complete physical and subjective testing remotely, including: (1) a grip strength assessment, conducted in triplicate on both hands using a digital hand dynamometer provided by the study team, and (2) completion of an electronic questionnaire including the Modified Fatigue Impact Scale (MFIS-21) and the Short Form-36 (SF-36) Health Survey. Instructions for standardized handgrip testing and survey completion will be provided electronically upon enrollment to the participant's email.
Following completion of baseline assessments, participants will begin daily supplementation of their prescribed study materials with their assigned treatment group: Quercefit® (500 mg/day), Ubiqsome™ (300 mg/day), or placebo, taken as one capsule in the morning and one capsule in the evening, for a total of two capsules daily over 12 weeks. Participants will be instructed to maintain consistent dosing of the supplement with water and will log compliance and adverse events routinely. Check-ins will occur at baseline, week 12, and periodically in between to monitor adherence and assess for adverse events.
On days 84 through 90 post-initial treatment, all baseline measures will be repeated following the same structure: a blood draw following an overnight fast, coordinated with the participant's preferred lab partner, followed that same week by remote grip strength testing and completion of the electronic questionnaires. Final adverse event assessments and compliance documentation will also be collected at this time. All procedures are designed to be completed remotely with direct coordination from study staff. Participants will be instructed to report any adverse events immediately and will receive regular contact throughout the study to support protocol adherence and data quality.
793 studies on the registry are indexed under Glucose Intolerance; 115 are open to participants now.
This study's planned enrollment of 60 is close to the median of 56 across 661 interventional studies indexed under Glucose Intolerance.
Browse Glucose Intolerance studies →Applied Science & Performance Institute is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
500 mg Quercefit® per day, administered as one 250 mg capsule taken twice daily (morning and evening)
Dietary Supplement: Quercetin (dietary supplement)
300 mg Ubiqsome™ per day, administered as one 150 mg capsule taken twice daily (morning and evening)
Dietary Supplement: Coenzyme Q10
One placebo capsule taken twice daily (morning and evening)
Dietary Supplement: Rice Flour
Natural compound found in foods like apples and onions that may help reduce inflammation and support overall health.
Substance made by the body that helps produce energy in cells and also acts as an antioxidant to support heart and overall health.
An inert carbohydrate used as the control treatment
Inflammaging (CIMKDM)
A fasting venous blood sample will be collected via venipuncture by a certified phlebotomist at the participant's designated Labcorp location following a minimum 10-hour overnight fast. Samples will be processed at a central laboratory using standardized assay protocols. Inflammaging (CIMKDM) is a biologically derived estimate of age, expressed in years, calculated from a composite of inflammatory biomarkers reflecting chronic low-grade inflammation and immune system activation. Higher values indicate a greater degree of inflammation-related biological aging.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Phenotypic Age
A fasting venous blood sample will be collected via venipuncture by a certified phlebotomist at the participant's designated Labcorp location following a minimum 10-hour overnight fast. Samples will be processed at a central laboratory. Phenotypic Age is a composite biomarker-based estimate of biological aging, expressed in years, derived from chronological age and nine clinical chemistry and hematological markers (albumin, creatinine, glucose, C-reactive protein, lymphocyte percentage, mean cell volume, red cell distribution width, alkaline phosphatase, and white blood cell count). Higher values relative to chronological age indicate accelerated biological aging.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Grip Strength
Handgrip strength will be assessed remotely using a digital hand dynamometer provided by the study team. Participants will perform three maximal isometric contractions on each hand, following standardized instructions for hand positioning and testing technique provided electronically at enrollment. The highest recorded value, in kilograms of force, will be used for analysis. This assessment serves as a practical indicator of overall muscle function and physical health.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Insulin Resistance (HOMA-IR)
Calculated from fasting glucose and fasting insulin values obtained via venipuncture blood draw at a Labcorp location following a minimum 10-hour overnight fast, using the standard HOMA-IR formula. Higher scores indicate greater insulin resistance.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Insulin Sensitivity (QUICKI)
Calculated from fasting glucose and fasting insulin values obtained via venipuncture blood draw at a Labcorp location following a minimum 10-hour overnight fast, using the standard QUICKI formula. Values typically range from approximately 0.3 to 0.4; higher values indicate better insulin sensitivity.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
High-Sensitivity C-Reactive Protein (hs-CRP)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory. hs-CRP is a marker of systemic inflammation, reported in mg/L. Higher values indicate greater inflammation.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Cortisol
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory. Cortisol serves as a marker of stress hormone status, reported in mcg/dL.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Lipid and Cardiovascular Risk Panel
A fasting venous blood sample will be collected via venipuncture at a Labcorp location following a minimum 10-hour overnight fast and processed at a central laboratory. The panel includes total cholesterol (mg/dL), triglycerides (mg/dL), HDL cholesterol (mg/dL), LDL cholesterol (mg/dL), VLDL cholesterol (mg/dL), and the total cholesterol/HDL ratio (a calculated, unitless ratio). Together, these values are used to assess cardiovascular risk and complement biological age estimates.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Uric Acid
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the kidney function panel. Reported in mg/dL.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Blood Urea Nitrogen (BUN)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the kidney function panel. Reported in mg/dL.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Creatinine
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the kidney function panel. Reported in mg/dL.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
BUN/Creatinine Ratio
Calculated from BUN and creatinine values obtained via the kidney function panel from a fasting venous blood sample. A calculated, unitless ratio used to assess kidney function.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Fatigue Impact (Modified Fatigue Impact Scale, MFIS-21)
Participants will complete the MFIS-21 electronically via a secure survey link provided at enrollment. The MFIS-21 is a 21-item self-report scale assessing the impact of fatigue on physical, cognitive, and psychosocial functioning. Each item is rated on a 5-point scale ranging from 0 ("never") to 4 ("almost always"). Item scores are summed to produce a total score ranging from 0 to 84. Higher total scores indicate greater fatigue impact (worse outcome).
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Health-Related Quality of Life (Short Form-36, SF-36)
Participants will complete the SF-36 electronically via a secure survey link provided at enrollment. The SF-36 assesses health-related quality of life across 8 domains: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Question responses range from 1 to 5 or 1 to 6 depending on the item, and each domain's responses are converted to a score from 0 to 100. For all domains, higher scores indicate greater well-being.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Estimated Glomerular Filtration Rate (eGFR)
Calculated from serum creatinine, age, and sex using a standard eGFR equation applied by the central laboratory. Reported in mL/min/1.73m².
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Sodium
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the electrolyte/mineral panel. Reported in mmol/L.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Potassium
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the electrolyte/mineral panel. Reported in mmol/L.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Chloride
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the electrolyte/mineral panel. Reported in mmol/L.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Calcium
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the electrolyte/mineral panel. Reported in mg/dL.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Phosphorus
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the electrolyte/mineral panel. Reported in mg/dL.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Iron
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the electrolyte/mineral panel. Reported in mcg/dL.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Total Protein
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the liver function panel. Reported in g/dL.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Albumin
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the liver function panel. Reported in g/dL.
Time frame: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Bilirubin (Total)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the liver function panel. Reported in mg/dL.
Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Alanine Aminotransferase (ALT)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the liver function panel. Reported in U/L.
Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Aspartate Aminotransferase (AST)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the liver function panel. Reported in U/L.
Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Alkaline Phosphatase (ALP)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the liver function panel. Reported in U/L.
Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Red Blood Cell Count (RBC)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in million cells/µL.
Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Hemoglobin
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in g/dL.
Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Hematocrit
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported as a percentage.
Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Mean Corpuscular Volume (MCV)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in fL.
Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Mean Corpuscular Hemoglobin (MCH)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in pg.
Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Mean Corpuscular Hemoglobin Concentration (MCHC)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in g/dL.
Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Red Cell Distribution Width (RDW)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported as a percentage.
Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
White Blood Cell Count with Differential (WBC)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in thousand cells/µL.
Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Platelet Count
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in thousand cells/µL.
Time frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Adverse events (AE)
Adverse events will be monitored continuously throughout the 12-week intervention via structured AE queries conducted by study staff through phone or secure digital check-in, in addition to participant self-report. All AEs will be documented and assessed for severity and relationship to the study product by the investigator.
Time frame: Time Frame: Baseline (Week 1) through Post-Intervention (Day 84 to 90)
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Quercetin
Applied Science & Performance Institute →